Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A general population-based cohort study

European Heart Journal

Volumn 39, Issue 39, 2018, Pages 3608-3614

  Ogdie, Alexis ^a   Kay McGill, Neilia ^b   Shin, Daniel B ^b   Takeshita, Junko ^b   Jon Love, Thorvardur ^c,d   Noe, Megan H ^b   Chiesa Fuxench, Zelma C ^b   Choi, Hyon K ^e   Mehta, Nehal N ^f   Gelfand, Joel M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ICELAND   (Iceland)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Deep venous thrombosis; Psoriasis; Psoriatic arthritis; Pulmonary embolus; Rheumatoid arthritis; Venous thromboembolism

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; INFLAMMATION; INTERMETHOD COMPARISON; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; COMPLICATION; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PSORIASIS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 85054960182     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx145     Document Type: Article

References (40)

1. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer-A cohort study using linked United Kingdom databases. Eur J Cancer 2013;49:1404-1413
2. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464-474
3. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-1846
4. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis: a systematic review of clinical studies. Thromb Haemost 2005;94:362-365
5. van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 2014;73:954-957
6. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009;101:134-138
7. Silvestri E, Scalera A, Emmi G, Squatrito D, Ciucciarelli L, Cenci C, Tamburini C, Emmi L, Di Minno G, Prisco D. Thrombosis in autoimmune diseases: a role for immunosuppressive treatments? Semin Thromb Hemost 2016; 42:650-661
8. Ogdie A, Yu Y, Haynes K, Love T, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi HK, Mehta NN, Gelfand JM. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: apopulation-based cohort study. Ann Rheum Dis 2015;74:326-332
9. Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1742
10. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano A.L., Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren VM Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381
11. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immunemediated diseases: record-linkage study. BMC Medical 2011;9. DOI: 10.1186/ 1741-7015-9-1
12. Holmqvist ME, Neovius M, Eriksson J, Mantel A, Wallberg-Jonsson S, Jacobsson LT, Askling J. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012;308:1350-1356
13. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:1600-1607
14. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis. QJM 2014;107: 793-797
15. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:297-304
16. Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 2013;72:1182-1187
17. Liang KP, Liang KV, Matteson EL, McClelland RL, Christianson TJ, Turesson C. Incidence of noncardiac vascular disease in rheumatoid arthritis and the relationship to extraarticular disease manifestations. Arthritis Rheum 2006;54:642-648
18. Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012;64:53-61
19. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow up study from Sweden. Lancet 2012;379:244-249
20. Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, Sung FC, Kao CH. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 2014;73:1774-1780
21. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic disease. Arthritis Res Ther 2014;16:435
22. Cegedim Strategic Data. The Health Improvement Network: our data. http:// csdmruk.cegedim.com/our-data/our-data.shtml (2 October 2013)
23. Chishom J. The Read clinical classification. BMJ 1990;300:1092
24. Watson DJ, Rhodes T, Bing C, Guess HA. Lower risk of thromboembolic cardiovascular events with Naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-1110
25. Garcia Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 2009;38:173-177
26. Seminara NM, Abuabara K, Shin DB, Langan SM, Kimmel SE, Margolis D, Troxel AB, Gelfand JM. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011;164:602-609
27. Ogdie A, Alehashemi S, Love T, Jiang Y, Haynes K, Hennessy S, Choi HK, Gelfand JM. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2014;23:918-922
28. Lawrenson R, Todd J, Leydon G, Williams T, Farmer R. Validation of the diagnosis of venous thromboembolism in general practice database studies. Pharmacoepidemiol Drug Saf 2000;49:591-596
29. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008;3. DOI: 10.1186/1751-0473-3-17
30. Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin Arthritis Rheum 2016;46:291-304
31. Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jorgensen CH, Olesen JB, Bretler DM, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One 2011;6:e18125
32. Lutsey OL, Prizment AE, Folsom AR. Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study. J Thromb Haemost 2012;10:708-711
33. Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating diseasemodifying antirheumatic drugs. Am J Med 2015;128:539. e7-517
34. Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol 2014;20:13863-13878
35. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011;31:153-164
36. Takeshita Jlm ER, Krishnamoorthy P, Moore J, Rogers WT, Zhang L, Gelfand JM, Mehta NN. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc 2014;3:e000507
37. Ungprasert P, Srivail N, Wijarnpreecha K, Charoenpong P, Knight EL. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford) 2015;54:736-742
38. Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sorensen HT. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013;173:743-753
39. Stuijver DJ, Majoor CJ, van 'Zaane B, Souverein PC, Boer A, Dekkers OM, Buller HR, Gerdes VE. Use of oral glucocorticoids and the risk of pulmonary embolus: a population-based case-control study. Chest 2013;143:1337-1342
40. Streiff MB. Predicting the risk of recurrent venous thromboembolism. J Thromb Thrombolysis 2015;39:353-366